Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN

Clinical trial NCT07187908 · RECRUITING

Trial details

NCT number: NCT07187908
Sponsor: Henan Cancer Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Primary/Secondary Prevention High Risk for Febrile Neutropenia of Chemotherapy Regimens Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in Febrile Neutropenia

Start date: 2025-01-01
Primary completion: 2026-10-01
Enrollment: 1076

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.